Alteration in the Immune Microenvironment Based on APC Status in MSS/pMMR Colon Cancer

Table 2

APC-mt and APC-wt MSS/pMMR colon cancer patients’ DCR for ICIs+chemotherapy.

	APC-mt MSS/pMMR patients	APC-wt MSS/pMMR patients
Treated with ICIs patients ()	20	15
ICIs in the first-line ()	12	10
CR	0	0
PR	2	0
SD	4	3
PD	6	7
ICIs in the second-line ()	8	5
CR	0	0
PR	1	0
SD	2	1
PD	5	4
Combined chemotherapy	20	15
XELOX	11	8
FORFOX	9	7
DCR in the first-line	6/12	3/10
DCR in the second-line	3/8	1/5
DCR in total	45%	26.7%